

C2
Claim 14 (twice amended) A topical hormonal composition with systemic effect of claim 1 containing a film-forming agent selected from the group consisting of cellulose, acrylic, methacrylic acid copolymers and polyvinylpyrrolidone.

REMARKS

Reconsideration of this application is requested in view of the amendments to the claims and the remarks presented herein.

Applicants are submitting herewith another copy of the specification which is a copy of the original filed application and does not contain any new matter.

With respect to the Examiner's objection to the expression "derivatives" in claims 11 and 14, these claims have now been amended to obviate this ground of rejection.

All of the claims have been rejected under 35 USC 103 as being obvious over the Saunal et al reference and the Winters et al reference taken in view of the Eibl et al patent, the Merck Index and Remington's Pharmaceutical Sciences. The Examiner states that the Saunal et al reference teaches a transdermal topical formulation using a solvent and absorption promoting agent, an active steroid and a film forming agent while Winters et al allegedly teaches a topical formulation of 19-nor progesterone for